Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
433- CUR,    Curcumin Inhibits the Migration and Invasion of Non-Small-Cell Lung Cancer Cells Through Radiation-Induced Suppression of Epithelial-Mesenchymal Transition and Soluble E-Cadherin Expression
- in-vitro, Lung, A549
E-cadherin↓, Vim↓, Slug↓, N-cadherin↓, Snail↓, MMP9↓, EMT↓,
432- CUR,    Curcumin-Induced Global Profiling of Transcriptomes in Small Cell Lung Cancer Cells
- in-vitro, Lung, H446
Bcl-2↓, cycF↓, LOX1↓, VEGF↓, MRGPRF↓, BAX↑, Cyt‑c↑, miR-548ah-5p↑,
431- CUR,    Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
ALDH1A1↓, CD133↓, EpCAM↓, OCT4↓, TAZ↓, Hippo↑, p‑TAZ↑,
430- CUR,    Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling
- vitro+vivo, Lung, A549
PTEN↑, MEG3↑,
457- CUR,    Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
TumCP↓, Apoptosis↑, TumAuto↑, P53↑, PI3K↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, Bcl-xL↓, LC3I↓, BAX↑, Beclin-1/ATG6↑, cl‑Casp3↑, cl‑PARP↑, LC3II↑, ATG3↑, ATG5↑,
438- CUR,    Curcumin Reduces Colorectal Cancer Cell Proliferation and Migration and Slows In Vivo Growth of Liver Metastases in Rats
- vitro+vivo, CRC, CC531
TumCP↓, TumVol↓, Albumin↑, ALP↑, AST↑, ALAT↑, ChE↓,
417- CUR,    Curcumin inhibits the growth of triple‐negative breast cancer cells by silencing EZH2 and restoring DLC1 expression
- vitro+vivo, BC, MCF7 - vitro+vivo, BC, MDA-MB-231 - vitro+vivo, BC, MDA-MB-468
EZH2↓, DLC1↑, cycA1/CCNA1↓, CDK1↓, Bcl-2↓, Casp9↑, DLC1↑,
420- CUR,    Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
Vim↓, Fibronectin↓, β-catenin/ZEB1↓, E-cadherin↓, CD44↑, CD24↓, OCT4↓, Nanog↓, SOX2↓,
422- CUR,    Curcumin induces re-expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines
- in-vitro, BC, HCC-38 - in-vitro, BC, T47D
BRCA1↑, TET1↑, DNMT3A↑, DNMT1↓, SNCG↓, miR-29b↓, miR-29b↑,
423- CUR,    Inhibition of TLR4/TRIF/IRF3 Signaling Pathway by Curcumin in Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
TLR4↓, IRF3↓, IFN-γ↓, TRIF↓,
424- CUR,    Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
Src↓, p‑STAT1↓, p‑Akt↓, p‑p44↓, p‑p42↓, RAS↓, Raf↓, Vim↓, β-catenin/ZEB1↓, P53↓, Bcl-2↓, Mcl-1↓, PIAS-3↑, SOCS-3↑, SOCS1↑, ROS↑, NF-kB↓, PAO↑, SSAT↑, P21↑, Bak↑,
425- CUR,    Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells
- in-vitro, BC, T47D - in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
CDC25↓, cDC2↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, BAX↑, Casp3↑,
426- CUR,    Use of cancer chemopreventive phytochemicals as antineoplastic agents
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, CAL51
Bcl-2↓, ROS↑, BAX↑, RAD51↑, γH2AX↑,
427- CUR,    Curcumin suppresses the malignancy of non-small cell lung cancer by modulating the circ-PRKCA/miR-384/ITGB1 pathway
- in-vitro, Lung, H1299 - in-vitro, Lung, H460 - vitro+vivo, Lung, A549
ITGB1↓, circ-PRKCA↓, miR-384↑,
429- CUR,    TAp63α Is Involved in Tobacco Smoke-Induced Lung Cancer EMT and the Anti-cancer Activity of Curcumin via miR-19 Transcriptional Suppression
- in-vitro, Lung, H1299 - in-vitro, Lung, A549
TAp63α↑, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, miR-19b↓,
447- CUR,  OXA,    Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway
- vitro+vivo, CRC, HCT116
p‑p65↓, Bcl-2↓, Casp3↑, EMT↓, p‑SMAD2↓, p‑SMAD3↓, N-cadherin↓, TGF-β↓, E-cadherin↑, TumVol↓, TumCMig↓,
456- CUR,    Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells
- vitro+vivo, GC, SGC-7901
miR-34a↑, TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, Bcl-2↓, CDK4/6↓, cycD1/CCND1↓,
455- CUR,    Curcumin Affects Gastric Cancer Cell Migration, Invasion and Cytoskeletal Remodeling Through Gli1-β-Catenin
- in-vitro, GC, SGC-7901
Shh↓, Gli1↓, FOXM1↓, β-catenin/ZEB1↓, TumCMig↓, Apoptosis↑, TumCCA↑, Wnt↓, EMT↓, E-cadherin↑, Vim↓,
454- CUR,    Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway
- in-vitro, GC, MGC803
TumCMig↓, TumCP↓, ROS↑, mtDam↑, DNAdam↑, Apoptosis↑, ATR↑, P21↑, p‑P53↑, GADD45A↑, p‑γH2AX↑,
453- CUR,    Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells
- in-vitro, GC, AGS
Bcl-2↓, survivin↓, BAX↑, TumCCA↑,
452- CUR,    Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells
- vitro+vivo, HNSCC, SCC9 - vitro+vivo, HNSCC, FaDu - vitro+vivo, HNSCC, HaCaT
TumCCA↑, PI3k/Akt/mTOR↓, Casp3↑, EGFR↓, EGF↑, PRKCG↑, p‑Akt↓, p‑mTOR↓, RPS6KA1↓, EIF4E↓, proCasp3↓,
451- CUR,    The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer
- vitro+vivo, HNSCC, SCC15 - vitro+vivo, HNSCC, SNU1076 - vitro+vivo, HNSCC, SNU1041
TumCMig↓, TumCG↓, PD-L1↓, PD-L2↓, Galectin-9↓, EMT↓, T-Cell↑, TILs↑, PD-1↓, TIM-3↓, CD4+↓, CD25+↓, FoxP3+↓, E-cadherin↑, CD8+↑, IFN-γ↑,
450- CUR,    Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT8
TumCP↓, TumCMig↓, CD44↓, CSCs↓,
449- CUR,    Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a
- vitro+vivo, CRC, SW480
TumCP↓, β-catenin/ZEB1↓, TCF↓, miR-21↓, NKD2↑, miR-130a↓,
448- CUR,    Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation
- in-vitro, CRC, HT-29
Apoptosis↑, TumCCA↑, p‑Akt↓, Akt↓, Bcl-2↓, p‑BAD↓, BAD↑, cl‑PARP↑, ROS↑, HSP27↑, Beclin-1/ATG6↑, p62↑, GPx1↓, GPx4↓,
446- CUR,    The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A Possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells
- in-vitro, CRC, SW480
IR↓, IGF-1↓, Myc↓, TumCMig↓, TumCP↓,
445- CUR,    Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT8 - in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
p‑AMPK↑, p‑ACC-α↑, NBR2↑, p‑S6K↓, mTOR↓,
444- CUR,  Cisplatin,    LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells
- vitro+vivo, CRC, HCT8
TumVol↓, Apoptosis↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑Casp3↑, cl‑PARP1↑, miR-497↑, KCNQ1OT1↓,
443- CUR,    Reduced Caudal Type Homeobox 2 (CDX2) Promoter Methylation Is Associated with Curcumin’s Suppressive Effects on Epithelial-Mesenchymal Transition in Colorectal Cancer Cells
- in-vitro, CRC, SW480
DNMT1↓, DNMT3A↓, N-cadherin↓, Vim↓, Wnt↓, Snail↓, Twist↓, β-catenin/ZEB1↓, E-cadherin↑, EMT↓, CDX2↓,
442- CUR,  5-FU,    Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress
- in-vitro, CRC, HCT116
Apoptosis↑, TumCP↓, TumCCA↑, TET1↑, NKD2↑, Wnt↓, EMT↓, Vim↑, E-cadherin↓, β-catenin/ZEB1↓, TCF↓, AXIN1↓,
441- CUR,    Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p
- in-vitro, CRC, HCT116
ERCC1↓, Bcl-2↓, GSTP1/GSTπ↓, MRP↓, P-gp/ABCB1↓, miR-409-3p↑, survivin↓,
440- CUR,    Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells
- vitro+vivo, CRC, SW480 - vitro+vivo, CRC, HT-29
NNMT↓, p‑STAT3↓, TumCP↓, TumCCA↑, ROS↑,
439- CUR,    Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway
- in-vitro, CRC, LGR5
Apoptosis↑, TumAuto↑, GP1BB↓, COL9A3↓, COMP↓, AGRN↓, ITGB4↓, LAMA5↓, COL2A1↓, ITGB6↓, LGR5↓, TFAP2A↓, ECM/TCF↓,
135- CUR,    Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TfR1/CD71↑, IRP1↑, IronCh↑, Casp↑, eff↑,
154- CUR,    Curcumin inhibits expression of inhibitor of DNA binding 1 in PC3 cells and xenografts
- vitro+vivo, Pca, PC3
Id1↓, TumCG↓,
136- CUR,  docx,    Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
Bcl-2↓, Bcl-xL↓, Mcl-1↓, BAX↑, BID↑, PARP↑, NF-kB↓, CDK1↓, COX2/PTGS2↓, RTK-RAS↓, PI3K/Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, ChemoSen↑,
137- CUR,    Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling
- in-vitro, Pca, DU145
NOTCH1↓, cycD1/CCND1↓, CDK2↓, P21↑, p27/CDKN1B↑, P53↑, Bcl-2↓, Casp3↑, Casp9↑, TumCCA↑, TumCP↓, Apoptosis↑,
140- CUR,    Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling
- in-vitro, Pca, PC3
CAFs/TAFs↓, EMT↓, ROS↓, CXCR4↓, IL6↓, MAOA↓, mTOR↓, HIF-1↓,
141- CUR,    Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer
- in-vivo, Pca, PC3
BAX↑, Bcl-2↓, TumCG↓, TumVol↓, TumW↓, Apoptosis↑, AR↓, Ca+2↑, MPT↑,
142- CUR,    Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts
- in-vivo, Pca, LNCaP
AR↓, PSA↓,
143- CUR,    Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species -mediated endoplasmic reticulum stress
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ER Stress↑, CHOP/DDIT3↑, GRP78/BiP↑, ROS↑, LC3II↑, eff↓, tumCV↓,
144- CUR,  Bical,    Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C
- in-vitro, Pca, PC3 - in-vitro, PC, DU145 - in-vitro, PC, LNCaP
p‑ERK↑, p‑JNK↓, MUC1↓, p65↓, AR↓, TumCG↓, MEK↑, SAPK↑,
161- CUR,  MeSA,    Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of Mcl-1 and FAK
- in-vitro, BC, MDA-MB-231 - in-vitro, Pca, DU145
Mcl-1↑, Mcl-1↓, MPT↑, AIF↑, chemoPv↑, Apoptosis↑, ROS↑, FAK↓, STAT3↓, NF-kB↓,
146- CUR,  EGCG,    Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
P21↑, TumCCA↑, TumCP↓, BioAv↓,
155- CUR,    Osteopontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells
- in-vitro, Pca, PC3
p‑ERK↓, VEGF↓, angioG↓, MMP2↓, MMP9↓, angioS↑,
151- CUR,    Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
AR↓, PSA↓, Dose↑,
152- CUR,    Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer
- in-vivo, Pca, NA
β-catenin/ZEB1↓, AR↓, STAT3↓, p‑Akt↓, Mcl-1↓, Bcl-xL↓, cl‑PARP↑, miR-21↓, miR-205↑, TumCG↓, TumCP↓, TumCI↓, angioG↓, TumMeta↓,
153- CUR,    Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo
- in-vivo, Pca, C4-2B
PSA↓, TGF-β↓, BMPs↑, TumMeta↓,
126- CUR,    Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
miR-34a↑, β-catenin/ZEB1↓, cMyc↓, P21↑, cycD1/CCND1↓, PCNA↓, TumCG↓,
117- CUR,    Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells
- in-vivo, Pca, RM-1 - in-vivo, Pca, DU145
ROS↑, tumCV↓, Apoptosis↑, TumCCA↑, Ca+2↑, eff↓, ER Stress↑,

Showing Research Papers: 2751 to 2800 of 8269
Prev Page 56 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GPx1↓, 1,   GPx4↓, 1,   GSTP1/GSTπ↓, 1,   IRP1↑, 1,   PAO↑, 1,   ROS↓, 1,   ROS↑, 8,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,   TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   CDC25↓, 1,   EGF↑, 1,   MEK↑, 1,   MPT↑, 2,   mtDam↑, 1,   p‑p42↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

p‑ACC-α↑, 1,   ALAT↑, 1,   p‑AMPK↑, 1,   cMyc↓, 1,   ERCC1↓, 1,   IR↓, 1,   NNMT↓, 1,   PI3K/Akt↓, 1,   PI3k/Akt/mTOR↓, 1,   p‑S6K↓, 1,   SSAT↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   p‑Akt↓, 6,   Apoptosis↑, 11,   BAD↑, 1,   p‑BAD↓, 1,   Bak↑, 1,   BAX↑, 8,   Bcl-2↓, 15,   Bcl-xL↓, 3,   BID↑, 1,   Casp↑, 1,   Casp3↑, 4,   cl‑Casp3↑, 2,   proCasp3↓, 1,   Casp9↑, 2,   Cyt‑c↑, 2,   Hippo↑, 1,   p‑JNK↓, 1,   Mcl-1↓, 4,   Mcl-1↑, 1,   MEG3↑, 1,   miR-497↑, 1,   miR-548ah-5p↑, 1,   Myc↓, 1,   p27/CDKN1B↑, 1,   survivin↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,   RTK-RAS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

COMP↓, 1,   EZH2↓, 1,   KCNQ1OT1↓, 1,   miR-205↑, 1,   miR-21↓, 2,   miR-409-3p↑, 1,   tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 1,   HSP27↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG3↑, 1,   ATG5↑, 1,   Beclin-1/ATG6↑, 2,   LC3I↓, 1,   LC3II↑, 2,   p62↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

ATR↑, 1,   BRCA1↑, 1,   DNAdam↑, 1,   DNMT1↓, 2,   DNMT3A↓, 1,   DNMT3A↑, 1,   GADD45A↑, 1,   NBR2↑, 1,   P53↓, 1,   P53↑, 3,   p‑P53↑, 1,   PARP↑, 1,   cl‑PARP↑, 3,   cl‑PARP1↑, 1,   PCNA↓, 1,   RAD51↑, 1,   SAPK↑, 1,   γH2AX↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↓, 1,   cycA1/CCNA1↓, 1,   cycD1/CCND1↓, 3,   cycF↓, 1,   P21↑, 7,   TAp63α↑, 1,   TFAP2A↓, 1,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH1A1↓, 1,   AXIN1↓, 1,   CD133↓, 1,   CD24↓, 1,   CD44↓, 1,   CD44↑, 1,   cDC2↓, 1,   CDX2↓, 1,   CSCs↓, 1,   EIF4E↓, 1,   EMT↓, 7,   EpCAM↓, 1,   p‑ERK↓, 1,   p‑ERK↑, 1,   FOXM1↓, 1,   Gli1↓, 1,   Id1↓, 1,   IGF-1↓, 1,   LGR5↓, 1,   miR-34a↑, 2,   mTOR↓, 2,   p‑mTOR↓, 3,   Nanog↓, 1,   NKD2↑, 2,   NOTCH1↓, 1,   OCT4↓, 2,   PI3K↓, 1,   PIAS-3↑, 1,   PRKCG↑, 1,   PTEN↑, 1,   RAS↓, 1,   RPS6KA1↓, 1,   Shh↓, 1,   SOX2↓, 1,   Src↓, 1,   p‑STAT1↓, 1,   STAT3↓, 2,   p‑STAT3↓, 1,   TAZ↓, 1,   p‑TAZ↑, 1,   TCF↓, 2,   TumCG↓, 6,   Wnt↓, 3,  

Migration(tgid=13) ⓘ

AGRN↓, 1,   Ca+2↑, 2,   CAFs/TAFs↓, 1,   CDK4/6↓, 1,   circ-PRKCA↓, 1,   COL2A1↓, 1,   COL9A3↓, 1,   DLC1↑, 2,   E-cadherin↓, 3,   E-cadherin↑, 5,   FAK↓, 1,   Fibronectin↓, 1,   Galectin-9↓, 1,   GP1BB↓, 1,   ITGB1↓, 1,   ITGB4↓, 1,   ITGB6↓, 1,   LAMA5↓, 1,   miR-130a↓, 1,   miR-19b↓, 1,   miR-29b↓, 1,   miR-29b↑, 1,   miR-384↑, 1,   MMP2↓, 1,   MMP9↓, 2,   MRGPRF↓, 1,   MUC1↓, 1,   N-cadherin↓, 4,   p‑p44↓, 1,   Slug↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   Snail↓, 2,   TET1↑, 2,   TGF-β↓, 2,   TumCI↓, 2,   TumCMig↓, 7,   TumCP↓, 12,   TumMeta↓, 2,   Twist↓, 1,   Vim↓, 6,   Vim↑, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 8,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   angioS↑, 1,   ECM/TCF↓, 1,   EGFR↓, 2,   HIF-1↓, 1,   LOX1↓, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

MRP↓, 1,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD25+↓, 1,   CD4+↓, 1,   COX2/PTGS2↓, 1,   CXCR4↓, 1,   FoxP3+↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IL6↓, 1,   NF-kB↓, 3,   p65↓, 1,   p‑p65↓, 1,   PD-1↓, 1,   PD-L1↓, 1,   PD-L2↓, 1,   PSA↓, 3,   SOCS-3↑, 1,   SOCS1↑, 1,   T-Cell↑, 1,   TILs↑, 1,   TLR4↓, 1,   TRIF↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

TIM-3↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

ChE↓, 1,   MAOA↓, 1,  

Protein Aggregation(tgid=19) ⓘ

SNCG↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 5,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   ChemoSen↑, 1,   Dose↑, 1,   eff↓, 2,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↑, 1,   Albumin↑, 1,   ALP↑, 1,   AR↓, 5,   AST↑, 1,   BMPs↑, 1,   BRCA1↑, 1,   EGFR↓, 2,   EZH2↓, 1,   FOXM1↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 1,   Myc↓, 1,   PD-L1↓, 1,   PSA↓, 3,  

Functional Outcomes(tgid=23) ⓘ

chemoPv↑, 1,   TumVol↓, 4,   TumW↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 1,   IRF3↓, 1,  
Total Targets: 249

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page